Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (APVO)
CUSIP: 03835L702
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 1,022,610
- Total 13F shares
- 20,293
- Share change
- +20,293
- Total reported value
- $191,356
- Price per share
- $9.43
- Number of holders
- 10
- Value change
- +$191,356
- Number of buys
- 10
Quarterly Holders Quick Answers
What is CUSIP 03835L702?
CUSIP 03835L702 identifies APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Recent filing periods for CUSIP 03835L702:
Top shareholders of APVO - Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| YA II PN, Ltd. |
13D/G
|
— |
10%
|
357,842
|
$1,663,965 | $0 | 16 Jun 2025 | |
| CVI Investments, Inc. |
13D/G
|
— |
8.2%
|
83,854
|
$744,624 | $0 | 31 Dec 2025 | |
| L1 Capital Global Opportunities Master Fund, Ltd. |
13D/G
|
— |
5%
|
164,300
|
$492,900 | -$362,100 | 14 Aug 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
9.1%
|
299,944
|
$434,919 | — | 30 Sep 2025 | |
| DRW Securities, LLC |
13F
|
Company |
4%
|
131,480
|
$190,646 | — | 30 Sep 2025 | |
| Ayrton Capital LLC |
13D/G
|
— |
10%
|
358,150
|
$107,445 | $0 | 30 Jun 2025 | |
| Virtu Financial LLC |
13F
|
Company |
1.2%
|
38,282
|
$56,000 | — | 30 Sep 2025 | |
| Hudson Bay Capital Management LP |
13D/G
|
— |
5%
|
76,598
|
$52,853 | $0 | 31 Dec 2024 | |
| Grady Grant III |
3/4/5
|
Director |
—
mixed-class rows
|
20,714
mixed-class rows
|
$20,135 | +$20,134 | 10 Nov 2025 | |
| Focus Partners Wealth |
13F
|
Company |
0.3%
|
10,000
|
$14,500 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.2%
|
6,500
|
$9,760 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.17%
|
5,673
|
$8,226 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.04%
|
1,445
|
$2,095 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0.02%
|
570
|
$827 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13D/G
3/4/5
13F
|
10%+ Owner · Company |
0%
|
86
|
$125 | -$715,879 | 31 Oct 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
74
|
$107 | — | 30 Sep 2025 | |
| Marvin L. White |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
30,012
mixed-class rows
|
$3 | — | 06 Aug 2025 | |
| Jeffrey G. Lamothe |
3/4/5
|
EVP, COO |
—
mixed-class rows
|
17,306
mixed-class rows
|
$1 | — | 06 Aug 2025 | |
| SoYoung Kwon |
3/4/5
|
SVP, GC, BD & Corp Affairs |
—
mixed-class rows
|
11,504
mixed-class rows
|
$1 | — | 06 Aug 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2025 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2025 | |
| BIGGER CAPITAL FUND L P |
13D/G
|
— |
10%
|
285,000
|
— | $0 | 18 Jun 2025 | |
| Fuad El-Hibri |
3/4/5
|
Director |
—
class O/S missing
|
87,697
|
— | — | 03 Dec 2021 | |
| Daphne Taylor |
3/4/5
|
SVP, CFO |
—
mixed-class rows
|
11,503
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Dirk Huebner |
3/4/5
|
SVP, CMO |
—
class O/S missing
|
11,500
|
— | — | 06 Aug 2025 | |
| Barbara Lopez Kunz |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Daniel Abdun-Nabi |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| John Niederhuber |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 | |
| Zsolt Harsanyi |
3/4/5
|
Director |
—
mixed-class rows
|
7,201
mixed-class rows
|
— | — | 06 Aug 2025 |
Institutional Holders of Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (APVO) as of Q4 2025
As of 31 Dec 2025,
Aptevo Therapeutics Inc. - Common Stock, $0.001 par value per share (APVO) was held by
10 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,293 shares.
The largest 10 holders included
VANGUARD GROUP INC, CITIGROUP INC, OSAIC HOLDINGS, INC., UBS Group AG, Tower Research Capital LLC (TRC), SBI Securities Co., Ltd., Tradewinds Capital Management, LLC, BANK OF AMERICA CORP /DE/, FMR LLC, and DANSKE BANK A/S.
This page lists
10
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
0
Q4 2025 holders
10
Holder diff
10
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.